Publication
Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study)
| dc.contributor.author | Ros, E | |
| dc.contributor.author | Oliván, J | |
| dc.contributor.author | Mostaza, JM | |
| dc.contributor.author | Vilardell, M | |
| dc.contributor.author | Pintó, X | |
| dc.contributor.author | Civeira, F | |
| dc.contributor.author | Hernández, A | |
| dc.contributor.author | Marques da Silva, P | |
| dc.contributor.author | Rodriguez-Botaro, A | |
| dc.contributor.author | Zambón, D | |
| dc.contributor.author | Lima, J | |
| dc.contributor.author | Gómez-Gerique, J | |
| dc.contributor.author | Díaz, C | |
| dc.contributor.author | Arístegui, R | |
| dc.contributor.author | Sol, JM | |
| dc.contributor.author | Hernández, G | |
| dc.date.accessioned | 2015-04-24T11:25:13Z | |
| dc.date.available | 2015-04-24T11:25:13Z | |
| dc.date.issued | 2003 | |
| dc.description.abstract | OBJECTIVE: Combined hyperlipidaemia is a common and highly atherogenic lipid phenotype with multiple lipoprotein abnormalities that are difficult to normalise with single-drug therapy. The ATOMIX multicentre, controlled clinical trial compared the efficacy and safety of atorvastatin and bezafibrate in patients with diet-resistant combined hyperlipidaemia. PATIENTS AND STUDY DESIGN: Following a 6-week placebo run-in period, 138 patients received atorvastatin 10mg or bezafibrate 400mg once daily in a randomised, double-blind, placebo-controlled trial. To meet predefined low-density lipoprotein-cholesterol (LDL-C) target levels, atorvastatin dosages were increased to 20mg or 40mg once daily after 8 and 16 weeks, respectively. RESULTS: After 52 weeks, atorvastatin achieved greater reductions in LDL-C than bezafibrate (percentage decrease 35 vs 5; p < 0.0001), while bezafibrate achieved greater reductions in triglyceride than atorvastatin (percentage decrease 33 vs 21; p < 0.05) and greater increases in high-density lipoprotein-cholesterol (HDL-C) [percentage increase 28 vs 17; p < 0.01 ]. Target LDL-C levels (according to global risk) were attained in 62% of atorvastatin recipients and 6% of bezafibrate recipients, and triglyceride levels <200 mg/dL were achieved in 52% and 60% of patients, respectively. In patients with normal baseline HDL-C, bezafibrate was superior to atorvastatin for raising HDL-C, while in those with baseline HDL-C <35 mg/dL, the two drugs raised HDL-C to a similar extent after adjustment for baseline values. Both drugs were well tolerated. CONCLUSION: The results show that atorvastatin has an overall better efficacy than bezafibrate in concomitantly reaching LDL-C and triglyceride target levels in combined hyperlipidaemia, thus supporting its use as monotherapy in patients with this lipid phenotype. | por |
| dc.identifier.citation | Clin Drug Investig. 2003;23(3):153-65 | por |
| dc.identifier.uri | http://hdl.handle.net/10400.17/2135 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Ebsco | por |
| dc.subject | HSM MED | por |
| dc.subject | Hyperlipidemias | por |
| dc.subject | Bezafibrate | por |
| dc.title | Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study) | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 165 | por |
| oaire.citation.startPage | 153 | por |
| oaire.citation.title | Clinical Drug Investigation | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |